The inflammation and cytokine milieu (IL-17 and IL-22) of active SLE patients could strongly induce differentiation of cTFH-17-CM toward effector phase and lead to migration into inflamed organs. The gene discussed is IL22; the disease is systemic lupus erythematosus.